| Original Research Online Published: 14 Nov 2022 | ||||||||||||
Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety Biswa Ranjan Routroy, Sailendra Narayan Parida, Lal Mohan Soy, Ashutosh Hota.
| ||||||||||||
| How to Cite this Article |
| Pubmed Style Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep. 2022; 6(16): 54-58. doi:10.5455/IJMRCR.172-1667475903 Web Style Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. https://www.mdpub.net/?mno=127109 [Access: April 02, 2025]. doi:10.5455/IJMRCR.172-1667475903 AMA (American Medical Association) Style Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep. 2022; 6(16): 54-58. doi:10.5455/IJMRCR.172-1667475903 Vancouver/ICMJE Style Routroy BR, Parida SN, Soy LM, Hota A. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep. (2022), [cited April 02, 2025]; 6(16): 54-58. doi:10.5455/IJMRCR.172-1667475903 Harvard Style Routroy, B. R., Parida, . S. N., Soy, . L. M. & Hota, . A. (2022) Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. Int J Med Rev Case Rep, 6 (16), 54-58. doi:10.5455/IJMRCR.172-1667475903 Turabian Style Routroy, Biswa Ranjan, Sailendra Narayan Parida, Lal Mohan Soy, and Ashutosh Hota. 2022. Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. International Journal of Medical Reviews and Case Reports, 6 (16), 54-58. doi:10.5455/IJMRCR.172-1667475903 Chicago Style Routroy, Biswa Ranjan, Sailendra Narayan Parida, Lal Mohan Soy, and Ashutosh Hota. "Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety." International Journal of Medical Reviews and Case Reports 6 (2022), 54-58. doi:10.5455/IJMRCR.172-1667475903 MLA (The Modern Language Association) Style Routroy, Biswa Ranjan, Sailendra Narayan Parida, Lal Mohan Soy, and Ashutosh Hota. "Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety." International Journal of Medical Reviews and Case Reports 6.16 (2022), 54-58. Print. doi:10.5455/IJMRCR.172-1667475903 APA (American Psychological Association) Style Routroy, B. R., Parida, . S. N., Soy, . L. M. & Hota, . A. (2022) Paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer: clinical efficacy and safety. International Journal of Medical Reviews and Case Reports, 6 (16), 54-58. doi:10.5455/IJMRCR.172-1667475903 |
